MedTrace Logo

Prevention of Cancer Development and Progression

NCT03940053 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of arginine in preventing cancer development

Conditions

Interventions

DRUG

Arginine hydrochloride

Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal

Sponsors & Collaborators

  • Zujiang YU

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-10
Primary Completion
2024-08-10
Completion
2025-05-10

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03940053 on ClinicalTrials.gov